Systematic Literature Review on the Impact of the Oscillating Positive Expiratory Pressure Therapy (Acapella) On Children with Refractory Mycoplasma Pneumoniae Pneumonia

Abstract

Children as patients who have refractory Mycoplasma pneumoniae pneumonia (RMPP) have difficult clinical issues. Most M. pneumoniae pneumonia infections are minor and self-limiting, but in some cases, especially in kids with underlying conditions like asthma or immune deficiencies, they can worsen and even become life-threatening. M. pneumoniae pneumonia may not usually respond well to standard antibiotic therapy, leading to extended hospital stays or even fatalities. Acapella treatment is a non-invasive technique used to mobilize secretions and improve lung function in individuals with respiratory illnesses. Acapella therapy may benefit children with refractory M. pneumoniae pneumonia, according to some research. Acapella device-based vibrating positive expiratory pressure (PEP) therapy has been proposed as a viable treatment for RMPP. The purpose of this comprehensive assessment of the literature was to assess how Acapella therapy affected kids with RMPP. To find pertinent papers published up to 2022, a thorough search was done using electronic databases like PubMed, SCOPUS and Google Scholar. Acapella therapy improved pulmonary function and oxygenation, shortened hospital stays, and lessened the need for mechanical ventilation in children with RMPP, according to an analysis of about 17 trials. Due to the small sample sizes and scarcity of randomized controlled trials, the quality of the data was, nonetheless, constrained. To confirm the utility of Acapella therapy in this demographic, additional research is required. Finally, acapella therapy seems to be a promising supplemental treatment for kids with RMPP. Healthcare professionals ought to think about including this therapy in their plans of care for these individuals.